Comments
Sudarshan Pharma Industries Ltd. is set to acquire a 100 per cent stake in Ratna Lifesciences Pvt. Ltd. through an all-cash deal worth ₹5.5 crore. The acquisition, expected to be finalised by August 30, 2023, positions Ratna Lifesciences as a wholly owned subsidiary of Sudarshan Pharma.
Ratna Lifesciences specialises in oncology products with an existing capacity of 2 metric tons, expandable to 15 metric tons. Ratna’s standing order book of nearly two metric tons, with a revenue potential of ₹15 crore and high EBITDA margins, presents a significant growth opportunity for Sudarshan Pharma. The future expansion plan could drive revenue potential to ₹55–60 crore annually.
However, the shares went down by 0.1 per cent to ₹72 at 11.17 am on BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.